A Cubillo1, A B Smith1, N Barrett1, V Giampietro2, M Brammer2, A Simmons2, K Rubia1. 1. Department of Child and Adolescent Psychiatry, Institute of Psychiatry, King's College London, London, UK. 2. Department of Neuroimaging, Institute of Psychiatry, King's College London, London, UK.
Abstract
BACKGROUND: The catecholamine reuptake inhibitors methylphenidate (MPH) and atomoxetine (ATX) are the most common treatments for attention deficit hyperactivity disorder (ADHD). This study compares the neurofunctional modulation and normalization effects of acute doses of MPH and ATX within medication-naive ADHD boys during working memory (WM). METHOD: A total of 20 medication-naive ADHD boys underwentfunctional magnetic resonance imaging during a parametric WM n-back task three times, under a single clinical dose of either MPH, ATX or placebo in a randomized, double-blind, placebo-controlled, cross-over design. To test for normalization effects, brain activations in ADHD under each drug condition were compared with that of 20 age-matched healthy control boys. RESULTS: Relative to healthy boys, ADHD boys underplacebo showed impaired performance only under high WM load together with significant underactivation in the bilateral dorsolateral prefrontal cortex (DLPFC). Both drugs normalized the performance deficits relative to controls. ATX significantly enhanced right DLPFC activation relative to MPH within patients, and significantly normalized its underactivation relative to controls. MPH, by contrast, both relative to placebo and ATX, as well as relative to controls, upregulated the left inferior frontal cortex (IFC), but only during 2-back. Both drugs enhanced fronto-temporo-striatal activation in ADHD relative to control boys and deactivated the default-mode network, which were negatively associated with the reduced DLPFC activation and performance deficits, suggesting compensation effects. CONCLUSIONS: The study shows both shared and drug-specific effects. ATX upregulated and normalized right DLPFC underactivation, while MPH upregulated left IFC activation, suggesting drug-specific laterality effects on prefrontal regions mediating WM.
RCT Entities:
BACKGROUND: The catecholamine reuptake inhibitors methylphenidate (MPH) and atomoxetine (ATX) are the most common treatments for attention deficit hyperactivity disorder (ADHD). This study compares the neurofunctional modulation and normalization effects of acute doses of MPH and ATX within medication-naive ADHDboys during working memory (WM). METHOD: A total of 20 medication-naive ADHDboys underwent functional magnetic resonance imaging during a parametric WM n-back task three times, under a single clinical dose of either MPH, ATX or placebo in a randomized, double-blind, placebo-controlled, cross-over design. To test for normalization effects, brain activations in ADHD under each drug condition were compared with that of 20 age-matched healthy control boys. RESULTS: Relative to healthy boys, ADHDboys under placebo showed impaired performance only under high WM load together with significant underactivation in the bilateral dorsolateral prefrontal cortex (DLPFC). Both drugs normalized the performance deficits relative to controls. ATX significantly enhanced right DLPFC activation relative to MPH within patients, and significantly normalized its underactivation relative to controls. MPH, by contrast, both relative to placebo and ATX, as well as relative to controls, upregulated the left inferior frontal cortex (IFC), but only during 2-back. Both drugs enhanced fronto-temporo-striatal activation in ADHD relative to control boys and deactivated the default-mode network, which were negatively associated with the reduced DLPFC activation and performance deficits, suggesting compensation effects. CONCLUSIONS: The study shows both shared and drug-specific effects. ATX upregulated and normalized right DLPFC underactivation, while MPH upregulated left IFC activation, suggesting drug-specific laterality effects on prefrontal regions mediating WM.
Authors: Susana Carmona; Elseline Hoekzema; Francisco X Castellanos; David García-García; Agustín Lage-Castellanos; Koene R A Van Dijk; Francisco J Navas-Sánchez; Kenia Martínez; Manuel Desco; Jorge Sepulcre Journal: Hum Brain Mapp Date: 2015-03-28 Impact factor: 5.038
Authors: Scott J Moeller; Anna B Konova; Dardo Tomasi; Muhammad A Parvaz; Rita Z Goldstein Journal: Psychopharmacology (Berl) Date: 2016-05-06 Impact factor: 4.530
Authors: Sheila Shanmugan; James Loughead; Ravi Prakash Reddy Nanga; Mark Elliott; Hari Hariharan; Dina Appleby; Deborah Kim; Kosha Ruparel; Ravinder Reddy; Thomas E Brown; C Neill Epperson Journal: Neuropsychopharmacology Date: 2016-08-23 Impact factor: 7.853
Authors: Louise Pape; Koen van Lith; Dick Veltman; Moran Cohn; Reshmi Marhe; Wim van den Brink; Theo Doreleijers; Arne Popma Journal: Front Psychiatry Date: 2021-06-17 Impact factor: 4.157